NCT00295971View on ClinicalTrials.gov

Donor Stem Cell Transplant in Treating Young Patients With Myelodysplastic Syndrome, Leukemia, Bone Marrow Failure Syndrome, or Severe Immunodeficiency Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Congenital Amegakaryocytic ThrombocytopeniaLeukemiaMyelodysplastic SyndromesSevere Congenital Neutropenia
Interventions
BIOLOGICAL

anti-thymocyte globulin

BIOLOGICAL

therapeutic allogeneic lymphocytes

DRUG

fludarabine phosphate

DRUG

thiotepa

PROCEDURE

allogeneic bone marrow transplantation

PROCEDURE

allogeneic hematopoietic stem cell transplantation

PROCEDURE

in vitro-treated peripheral blood stem cell transplantation

RADIATION

total-body irradiation

Trial Locations (2)

94115

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco

27599-7295

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of California, San Francisco

OTHER

NCT00295971 - Donor Stem Cell Transplant in Treating Young Patients With Myelodysplastic Syndrome, Leukemia, Bone Marrow Failure Syndrome, or Severe Immunodeficiency Disease | Biotech Hunter | Biotech Hunter